SITC-Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship

Award Amount: $200,000 (two-year)

Recipient: Elisa Bergaggio, PhD

Institution: Boston Children’s Hospital

Project Title: “Enhancing ALK.CAR-T efficacy in solid tumors”

SITC-MRA Women in Melanoma Fellowship

Award Amount: $200,000 (two-year)

Recipient: Arielle Elkrief, MD

Institution: University of Montreal

Project Title: “Identification of the next generation of microbiome therapeutics in combination with immune checkpoint blockade to improve outcomes for patients with melanoma”

SITC-Merck Cancer Immunotherapy Clinical Fellowship

Award Amount: $100,000 (one-year)

Recipient: Benjamin R. Schrank, MD, PhD

Institution: The University of Texas MD Anderson Cancer Center

Project Title: “Enhancing Tumor-Immune Interactions in Breast Cancer via an Immunostimulatory Antibody-Drug Conjugate

SITC Diversity, Equity and Inclusion Fellowship

Award Amount: $100,000 (one-year)

Recipient: Victor Arrieta, MD, PhD

Institution: Northwestern University

Project Title: “Leveraging DNA Methylation Signatures to Decode Clinical Responses to Immune Checkpoint Blockade in Glioblastoma”

SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship

Award Amount: $40,000 (one-year)

Recipient: Gabriele Casirati, MD, PhD

Institution: Dana-Farber Cancer Institute

Project Title: “Epitope edited Hematopoietic Stem Cells to Eliminate On-target/Off-tumor Toxicity”

SITC-Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship

Award Amount: $200,000 (two-year)

Recipient: Tyler E. Miller, MD, PhD

Institution: Massachusetts General Hospital

Project Title: "Identifying interventions that target the immunosuppressive microenvironment in solid tumors"

SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship

Award Amount: $100,000 (one-year)

Recipient: Pamela Basto, MD, PhD

Institution: Stanford University

Project Title: "Development of Cellular Therapies Targeting Aberrant Glycosylation in Lung Adenocarcinoma"

SITC-Merck Cancer Immunotherapy Clinical Fellowship

Award Amount: $100,000 (one-year)

Awardee: Eisuke Tomiyama, MD, PhD

Institution: University of British Columbia

Project Title: "Elucidation of the role of EphA2 in the immune evasion of bladder cancer to overcome resistance to immune-checkpoint inhibitors"

SITC-Genentech Women in Cancer Immunotherapy Fellowship

Award Amount: $100,000 (one-year)

Recipient: Kylynda C. Bauer, PhD

Institution: National Cancer Institute

Project Title: "Vagal-CD8+ T cell axis: Harnessing neuroimmune circuits to alter anti-tumor immunity in liver cancer"

SITC Diversity, Equity and Inclusion Fellowship

Award Amount: $100,000 (one-year)

Recipient: Shaquia L. Idlett-Ali, PhD

Institution: University of Colorado

Project Title: "Targeting nerve-mediated immunosuppression in the tumor microenvironment for head and neck squamous cell carcinoma"

SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship

Award Amount: $40,000 (one-year)

Recipient: Guido Ghilardi, MD

Institution: University of Pennsylvania

Project Title: "The role of lymphodepletion in CAR T cell-associated toxicities"

2024 NCI Immunotherapy Fellowship

Award: This one-year program allows the fellow to have exposure to multiple clinical immunotherapeutic approaches and also to key opinion leaders in the field of clinical immunotherapy. Co-Sponsored by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and SITC, made possible in part by an educational grant from EMD Serono.

Awardee: Julie Ma, MD

Institution: University of California, Los Angeles

SITC-Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship

Award Amount: $200,000 (two-year)

Recipient: Simone Minnie, PhD

Institution: Fred Hutchinson Cancer Research Center

Project Title: “Harnessing Treg fragility to improve anti-myeloma immune responses”

SITC-Amgen Cancer Immunotherapy in Hematologic Malignancies Fellowship

Award Amount: $100,000 (one-year)

Recipient: John Ligon, MD

Institution: University of Florida

Project Title: “Leveraging CD70 CXCR2-modified CAR T-cells for treating AML”

SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship

Award Amount: $100,000 (one-year)

Recipient: Jonathan Chen, MD, PhD

Institution: Massachusetts General Hospital

Project Title: “Dissecting the tumor immunity multicellular network”

SITC-Merck Cancer Immunotherapy Clinical Fellowship

Award Amount: $100,000 (one-year)

Awardee: Hitomi Hosoya, MD, PhD

Institution: Stanford University

Project Title: “Cell-free DNA-based Platform to Determine Treatment Response and Resistant Mechanisms to CAR T-cell Therapy in Multiple Myeloma"

SITC-Genentech Women in Cancer Immunotherapy Fellowship

Award Amount: $50,000 (one-year)

Recipient: Shu-chin Lai, PhD

Institution: Huntsman Cancer Institute, University of Utah

Project Title: “Augmenting T cell immunity to facilitate metastatic breast cancer treatment”

SITC-Nektar Therapeutics Equity and Inclusion in Cancer Immunotherapy Fellowship

Award Amount: $50,000 (one-year)

Recipient: Mara De Martino, PhD

Institution: Weill Cornell Medicine

Project Title: “Targeting FASN to sensitize irradiated glioblastoma to immunotherapy”

SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship

Award Amount: $40,000 (one-year)

Recipient: Steven Blum, MD

Institution: Dana-Farber Cancer Institute, Massachusetts General Hospital

Project Title: “Distinguishing Immune-Related Adverse Events (irAEs) from Anti-Tumor Immunity”

SITC-Natera ctDNA in Immunotherapy Response Monitoring Fellowship and Technology Award

Award: $40,000 and access to Natera’s Signatera™ testing technology

Recipient: Mariya Rozenblit, MD

Institution: Yale University

Project Title: “The tumor microenvironment of triple negative breast cancers with detectable circulating tumor DNA after pembrolizumab treatment”

SITC-NanoString Technologies Single Cell Biology Award

Award: Access to NanoString Technologies’ CosMx™ Spatial Molecular Imager (SMI)

Recipient: Elshad Hasanov, MD, PhD

Institution: University of Texas MD Anderson Cancer Center

Project Title: “CosMxing renal cell carcinoma brain metastases to decipher immune checkpoint inhibitor resistance mechanisms at single-cell and spatial context”

2022 NCI Immunotherapy Fellowship

Award: This one-year program allows the fellow to have exposure to multiple clinical immunotherapeutic approaches and also to key opinion leaders in the field of clinical immunotherapy. Co-Sponsored by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and SITC, made possible in part by an educational grant from EMD Serono.

Awardee: Elisabetta Xue, MD

Institution: San Raffaele Hospital

2022 NCI Immunotherapy Fellowship

Award: This one-year program allows the fellow to have exposure to multiple clinical immunotherapeutic approaches and also to key opinion leaders in the field of clinical immunotherapy. Co-Sponsored by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and SITC, made possible in part by an educational grant from EMD Serono.

Awardee: Alexander Rankin, MD

Institution: Children's Hospital Colorado, University of Colorado School of Medicine

SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship

Award: This one-year program allows the fellow to have exposure to multiple clinical immunotherapeutic approaches and also to key opinion leaders in the field of clinical immunotherapy. Co-Sponsored by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and SITC, made possible in part by an educational grant from EMD Serono.

Awardee: Dara Bracken-Clarke, BMed, BCh, BAO

Institution: Waterford University Hospital, Ireland

SITC-Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship

Recipient: Karlo Perica, MD, PhD

Institution: Memorial Sloan Kettering Cancer Center

Project Title: “Allogeneic CAR T Cell Therapy: Overcoming Host-Versus-Graft Immunity”

Award Amount: $200,000 (two-year)

SITC-Amgen Cancer Immunotherapy in Hematologic Malignancies Fellowship

Recipient: Benjamin Goldenson, MD, PhD

Institution: University of California, San Diego

Project Title: “Chimeric Antigen Receptor Natural Killer Cells for the Treatment of Acute Myeloid Leukemia”

Award Amount: $100,000 (one-year)

SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship

Recipient: Biagio Ricciuti, M

Institution: Dana-Farber Cancer Institute

Project Title: “Dissecting the genomic correlates of response and acquired resistance to PD-(L)1 inhibition in non-small cell lung cancer”

Award Amount: $100,000 (one-year)

SITC-Merck Cancer Immunotherapy Clinical Fellowship

Recipient: Elen Torres, PhD

Institution: Koch Institute for Integrative Cancer Research at MIT

Project Title: “The role of tumor cell-intrinsic Sox2 in the anti-tumor immune response in non-small cell lung cancer (NSCLC)”

Award Amount: $50,000 (one-year)

2021 NCI Immunotherapy Fellowship

Recipient: Vincent I. Poon, MD

Institution: BC Cancer Vancouver

Award: Co-Sponsored by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and SITC, made possible in part by an educational grant from EMD Serono. This 1-year program allows the fellow to have exposure to multiple clinical immunotherapeutic approaches and also to key opinion leaders in the field of clinical immunotherapy. Click here for more information on this fellowship.

SITC-Nektar Therapeutics Equity and Inclusion in Cancer Immunotherapy Fellowship

Recipient: Nicholas Tschernia, MD

Institution: University of North Carolina at Chapel Hill

Co-Sponsored by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and SITC, made possible in part by an educational grant from EMD Serono. This 1-year program allows the fellow to have exposure to multiple clinical immunotherapeutic approaches and also to key opinion leaders in the field of clinical immunotherapy.

SITC-Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship

Recipient: Li Qiang, PhD

Institution: Dana-Farber Cancer Institute, Harvard Medical School

Project Title: “Signaling pathways in tumoricidal macrophages in pancreatic cancer”

Award Amount: $200,000 (two year)

SITC-Amgen Cancer Immunotherapy in Hematologic Malignancies Fellowship

Recipient: Suman Paul, MBBS, PhD

Institution: Johns Hopkins School of Medicine

Project Title: “T cell receptor variable gene targeting for T cell cancer immunotherapy”

Award Amount: $100,000 (one year)

SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship

Recipient: Jacob Kaufman, MD, PhD

Institution: Duke University Medical Center

Project Title: “Strategies to overcome immunotherapy resistance in LKB1 and KEAP/NRF2 mutated NSCLC: modulating ferroptosis to restore immune sensitivity”

Award Amount: $100,000 (one year)

SITC-Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship

Recipient: Joseph Clara, MD

Institution: National Institutes of Health (NIH)

Project Title: “CRISPR-Cas9-based gene editing to enhance cytotoxicity of natural killer cells against multiple myeloma”

Award Amount: $100,000 (one year)

SITC-Amgen Cancer Immunotherapy in Hematologic Malignancies Fellowship

Recipient: Natalie Vokes, MD

Institution: Dana-Farber Cancer Institute

Project Title: “Dissecting the molecular mediators of treatment response and resistance evolution in NSCLC"

Award Amount: $50,000 (one year)

SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship

Recipient: Kipp Weiskopf, MD, PhD

Institution: Whitehead Institute for Biomedical Research

Project Title: “Engaging macrophages to eliminate cancers with driver mutations”

Award Amount: $50,000 (one year)

2020 NCI Immunotherapy Fellowship

Recipient: John Shin, MD

Institution: Mayo Clinic Rochester

Co-Sponsored by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and SITC, made possible in part by an educational grant from EMD Serono. This 1-year program allows the fellow to have exposure to multiple clinical immunotherapeutic approaches and also to key opinion leaders in the field of clinical immunotherapy.

SITC-Amgen Cancer Immunotherapy in Hematologic Malignancies Fellowship Award

Awardee: May Daher, MD

Institution: The University of Texas MD Anderson Cancer Center

Project Title: “CIS checkpoint deletion in cord blood derived iC9.CAR19.IL-15 NK cells to treat B-cell hematologic malignancies”

Award Amount: $100,000; one-year

SITC-AstraZeneca Immunotherapy in Lung Cancer (Early Stage NSCLC) Clinical Fellowship Award

Awardee: Chen Zhao, MD

Institution: National Institutes of Health

Project Title: “Investigating microbiota-immune interaction in patients with Non-Small Cell Lung Cancer”

Award Amount: $100,000; one-year

SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship

Awardee: Yimin (Victor) Du, PhD

Institution: The Salk Institute for Biological Studies

Project Title: “Fine-Tuning Natural Killer Cells to Target T-Cell Resistant Tumors”

Award Amount: $100,000; one-year

2019 NCI Immunotherapy Fellowship Recipient

Recipient: Lekha Mikkilineni, MD
National Cancer Institute, National Institutes of Health, United States

This fellowship was co-sponsored by the National Cancer Institute and SITC and made possible in part by an educational grant from EMD Serono.

SITC-MRA Young Investigator in Immune-Related Adverse Events Award Recipient

Recipient: Shaheen Khan, PhD, University of Texas Southwestern Medical Center

Project Title: Investigating Host Immune Factors in Mediating Immune-Related Adverse Events

Co-sponsored by the Melanoma Research Alliance and SITC.

SITC-Bristol-Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship Award

Recipient: David Liu, MD, MPH, MS, Dana-Farber Cancer Institute

Project Title: “Dissecting Differential Response to Immunotherapy in Melanoma through Clinical Computational Oncology”

Award Amount: $200,000 (two years)

SITC-AstraZeneca Postdoctoral Cancer Immunotherapy in Combination Therapies Clinical Fellowship Award

Recipient: Bryan D. Choi, MD, PhD, Massachusetts General Hospital and Harvard Medical School

Project Title: “Combination Immunotherapy with Chimeric Antigen Receptor T cells and Bispecific T-cell Engagers for Glioblastoma”

Award Amount: $100,000 (one year)

SITC-Merck Cancer Immunotherapy Clinical Fellowship Award

Recipient: Kelly G. Paulson, MD, PhD, Fred Hutchinson Cancer Research Center

Project Title: “Turning immunotherapy responses into immunotherapy cures for the virus-associated Merkel cell carcinoma”

Award Amount: $100,000 (one year)

2018 NCI Immunotherapy Fellowship Recipient

Jason Redman, MD
National Cancer Institute, National Institutes of Health, United States

Co-sponsored by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and SITC and made possible in part by an educational grant from EMD Serono.

2017 SITC-Merck Immunotherapy in Lung Cancer Clinical Fellowship Recipient

Recipient: Arnab Ghosh, MD, PhD - Memorial Sloan-Kettering Cancer Center

Project Title: "Enhancing antitumor immunity mediated by costimulatory agents through reprogramming myeloid infiltrating cells"

Award Amount: $100,000 for one year

2017 SITC’s Holbrook Kohrt, MD, PhD Cancer Immunotherapy Translational Memorial Fellowship Recipient

Recipient: Nathan Singh, MD, MS - University of Pennsylvania

Project Title: "Enhancing CAR T cell efficacy by  disrupting immune inhibition"

Award Amount: $100,000 for one year

SITC-Merck Cancer Immunotherapy Clinical Fellowship Award

Recipient: Ariel E. Marciscano, MD - Johns Hopkins University

Co-sponsored by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and SITC and made possible in part by an educational grant from EMD Serono.

SITC-AstraZeneca Cancer Immunotherapy Clinical Fellowship in Non-Small Cell Lung Cancer (NSCLC) Recipient

Recipient: Miguel F. Sanmamed, MD, PhD - Yale University

Project Title: “Identifying primary and acquired resistance mechanisms to PD-1/PD-L1 pathway blockade in non-small cell lung cancer patients using immune-patient-derived xenograft model”

Award Amount: $100,000 for one year

SITC-Genentech Cancer Immunotherapy Clinical Fellowship in Related Biomarkers or Mechanism of Action (MOA) Recipient

Recipient: Claire F. Friedman, MD - Memorial Sloan Kettering Cancer Center

Project Title: “The tumor immune microenvironment and response to CTLA-4 blockade in PD-1 refractory metastatic melanoma”

Award Amount: $40,000 for one year

SITC-Bristol-Myers Squibb Cancer Immunotherapy Translational Fellowship

Recipient: Ariel E. Marciscano, MD - Johns Hopkins University

Project Title: “Dissecting the role of tissue-specific anti-tumor immunity following PD-1 blockade”

Award Amount: $200,000 for two years

SITC-EMD Serono Cancer Immunotherapy Clinical Fellowship Recipient

Recipient: Eric L. Smith, MD, PhD - Memorial Sloan Kettering Cancer Center

Project Title: “Investigating and manipulating the interplay between the tumor microenvironment and Chimeric Antigen Receptor T cell therapy to generate durable remissions in multiple myeloma”

Award Amount: $100,000 for one year

SITC-Genentech Cancer Immunotherapy Basic Fellowship in Related Biomarkers Recipient

Recipient: Ada G. Blidner, MSc, PhD - Immunopathology Laboratory, Institute of Biology and Experimental Medicine

Project Title: “Unraveling the role of the galectin-1/glycan axis in T cell exhaustion and resistance to cancer immunotherapy”

Award Amount: $40,000 for one year

SITC-MRA Young Investigator Award Recipient

Recipient: Ping-Chih Ho, PhD - University of Lausanne

Project Title: “Immunometabolic editing facilitates immune evasion in melanomas”

Award Amount: $225,000 for three years

2016 NCI Immunotherapy Fellowship Recipient

Recipient: Julius Strauss, MD - National Cancer Institute, National Institutes of Health

Co-Sponsored by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and SITC, made possible in part by an educational grant from EMD Serono. This 1-year program allows the fellow to have exposure to multiple clinical immunotherapeutic approaches and also to key opinion leaders in the field of clinical immunotherapy.

2015 Fellowship Recipient

This 2015 SITC Fellowship Awards were made possible through the generosity of Merck.

SITC-AstraZeneca Cancer Immunotherapy Clinical Fellowship in Non-Small Cell Lung Cancer (NSCLC) Recipient

Recipient: Jonathan Peled, MD, PhD, - Memorial Sloan Kettering Cancer Center

The Society for Immunotherapy of Cancer (SITC) is pleased to announce Jonathan Peled, MD, PhD, of Memorial Sloan Kettering Cancer Center, as the recipient of the SITC-Merck Cancer Immunotherapy Clinical Fellowship Award. This award supports the development of the next generation of immunotherapy experts through dedicated funding of novel research. With a shortage of U.S. physicians specializing in oncology predicted to occur by 2025, it is important now, more than ever, to secure the future of cancer immunotherapy research.

Jonathan%20Peled.jpgDr. Peled was selected as the recipient of this award for his project, titled, “Evaluation of the Effect of Microbiota on Graft-versus-Tumor Activity in Hematological Malignancies.”

“I am honored to have been selected for this opportunity, and I am grateful to the Society for Immunotherapy of Cancer and to Merck for their interest in my research,” said Dr. Peled. “With this support, I hope to continue my investigation into how the community of microbes residing in our intestines affect the immune system’s response to cancer. I feel fortunate to be embarking on my career now because we have so many new tools that help make this work possible.”

Established through a strategic partnership between SITC and Merck, this one-year, $100,000 award comes at an extremely important time in cancer research as immunotherapy, a type of treatment that uses the power of an individual’s immune system to recognize and attack cancer cells, is shrinking tumors in several cancer types and allowing patients to live longer when compared to other standard of care treatments such as radiation and chemotherapy. 

“I am delighted that Dr. Peled has been selected as the 2015 SITC-Merck Fellowship awardee,” said SITC President Howard L. Kaufman, MD, FACS. “The work proposed represents innovative research with the potential to impact the field of immunotherapy and supports a most promising young investigator who is clearly dedicated to improving our understanding of tumor immunotherapy.” 

“Merck is thrilled to help honor this year’s award winner,” said Roger D. Dansey, MD, Senior Vice President, Global Clinical Development, Oncology, Merck Research Laboratories. “We believe fellowship opportunities like this not only inspire the scientific community but have the potential to lead to meaningful developments in cancer immunotherapy research.”

The SITC-Merck Cancer Immunotherapy Clinical Fellowship Award is provided by SITC’s Forward Fund and supported by an independent educational grant from Merck (known as MSD outside the U.S. and Canada). Established in 2012, the Forward Fund aims to stimulate the future of the science, development and application of cancer immunology and immunotherapy through financially supporting its education and research.

“Following the completion of my fellowship, I plan to continue my career in hematologic oncology, with a focus on understanding the basic mechanisms of the diseases and treatments. I also plan to continue my work in directly caring for patients who receive bone marrow transplants,” said Dr. Peled. 

Dr. Peled was recognized for this fellowship during an Awards Ceremony on November 7, 2015 as part of the SITC 30th Anniversary Annual Meeting & Associated Programs held in National Harbor, Maryland, November 4 – 8, 2015.

2014 Fellowship Recipient

This 2014 SITC Fellowship Awards were made possible through the generosity of Merck.

2014 SITC-EMD Serono Cancer Immunotherapy Clinical Fellowship Award

Recipient: Marco Ruella, MD - University of Pennsylvania

The Society for Immunotherapy of Cancer (SITC) is pleased to announce that SITC member, Marco Ruella, MD of the University of Pennsylvania, is the recipient of the 2014 SITC-EMD Serono Cancer Immunotherapy Clinical Fellowship Award. This award is the first of its kind offered by the Society. Congratulations Dr. Ruella!

RuellaMarco2.pngDr. Ruella was selected as the winner of this award for his project, titled, “Duel Chimeric Antigen Receptor T Cell Therapy for Human B-Cell Acute Lymphoblastic Leukemia.”

“I’m very honored to be the first recipient of this fellowship award and I would like to thank the Society and the award committee for choosing my project,” said Dr. Ruella. “The goal of my research project is to treat patients with relapsing or refractory B-cell Leukemia with Chimeric Antigen Receptor T cells targeting multiple antigens, in order to avoid tumor escape. As powerful new therapies are developed that enhance the immune response to malignancy, it will be important for us to stay ahead of cancer’s escape mechanisms.  One way to do this is with combination therapies.”

This year’s award was established through the generosity of EMD-Serono and is intended to support the development of the next generation of immunotherapy experts. Through this funding of novel research, the Society intends to cultivate those individuals who have a vested interest in furthering the clinical research and translation of cancer immunotherapy.  The Society wishes to thank EMD-Serono for their partnership in offering this one-year, $100,000 award, as it comes at an extremely important time in cancer research.

“In order to continue to propel the field forward, SITC is committed to furthering research and education opportunities primarily for early career scientists,” said SITC’s Vice President, Dr. Howard Kaufman. “Through this type of support, we can discover innovative research and development projects that can bring us closer to identifying new immunotherapies to help cancer patients in need.”

Dr. Ruella will be highlighted on Saturday, November 8, 2014 at the Award Ceremony to be held during the Society’s Annual Meeting in National Harbor, MD. (November 7-9, 2014).  Dr. Ruella will also speak about his fellowship experience during the Professional Development Session held on November 9th, as part of the SITC Annual Meeting & Associated Programs.

“The SITC-EMD Serono Cancer Immunotherapy Clinical Fellowship Award has a central role in my career development and long-term in promoting the transition towards an independent position as an investigator bridging the gap between the laboratory and the clinic,” said Ruella. “In addition, as my first major successful grant, this award helps to provide much-needed confidence on the road to further funding applications.”